A randomised, placebo-controlled, double-blinded, cross-over, Phase 1 study evaluating the safety and preliminary efficacy of the GLP 1 analogue ROSE-010 on appetite and food intake in overweight and obese subjects.
Phase 1
- Conditions
- Overweight, ObesityMedDRA version: 20.0Level: PTClassification code: 10033307Term: Overweight Class: 100000004861MedDRA version: 20.0Level: PTClassification code: 10029883Term: Obesity Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- CTIS2023-507758-34-00
- Lead Sponsor
- Rose Pharma Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method